In addition to Agomab, John is the chair of the board of Adcendo (DK), CatalYm (DE), Solid Therapeutics (DK), and Synklino (DK), as well as a non-executive director of Neophore and Storm (both UK). Prior, he was the CEO of F-star Therapeutics in Cambridge, UK (2012-18), VP Research at ImClone Systems, New York (2010-12), and Chief Scientific Officer and Co-Founder of Symphogen, Denmark (2000-09). After his medical degree in Aarhus, Denmark, John received a DPhil in Immunology from University of Oxford, England.